Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone versus prednisolone taper for glucocorticoid withdrawal
ACTRN12621000614897Phase 4Not yet recruiting
- Sponsor
- Warwick Inder
- Start
- Jun 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Adrenal suppression and hypoadrenocorticism comparing Hydrocortisone taper arm with Prednisolone slow wean arm (2 arms). Primary endpoint: Percent of participants with normal pituitary-adrenal function at 12 weeks. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
hydrocortisoneprednisolone
03
Conditions
Adrenal suppressionhypoadrenocorticism
Beyond the preview
Go deeper on ACTRN12621000614897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000614897.